Therapeutic Asset Ratings
3,187 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
a2b530
Malignant Pancreatic Neoplasm
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b543
Colorectal Adenocarcinoma
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b543
Ovarian Neoplasm
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b543
Malignant Pancreatic Neoplasm
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b543
Rectal Carcinoma
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b694
Colorectal Adenocarcinoma
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b694
Ovarian Neoplasm
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b694
Malignant Pancreatic Neoplasm
A2 Biotherapeutics Inc.
P1/2
CC
(43)
a2b694
Rectal Carcinoma
A2 Biotherapeutics Inc.
P1/2
CC
(43)
Adoptive Therapy With Autologous Mc2 Tcr T Cells
Head And Neck Cancer
Erasmus Medical Center
P1/2
CC
(43)
Allogeneic Natural Killer Cells
Cholangiocarcinoma
Medigen Biotechnology Corporation
P1/2
CC
(43)
Allogeneic Natural Killer Cells
Pancreatic Adenocarcinoma
Medigen Biotechnology Corporation
P1/2
CC
(43)
Allogeneic Tcr-Enhanced Vδ2 T Cell
Hematopoietic And Lymphoid Cell Neoplasm
Chinese PLA General Hospital
P1/2
CC
(43)
Allo-Quadcar01-T
Hematopoietic And Lymphoid Cell Neoplasm
AvenCell Therapeutics, Inc.
P1/2
CC
(43)
Anti-Cd19 Autologous Car-T Cell Infusion
B-Cell Non-Hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
P1/2
CC
(43)
Anti-Cd19 Ucar-Nk Cells
B-Cell Non-Hodgkin Lymphoma
Kunming Hope of Health Hospital
P1/2
CC
(43)
Anti-Cd33 Cart
Acute Myeloid Leukemia
Essen Biotech
P1/2
CC
(43)
Anti-Kras G12V Mtcr Pbl
Rectal Carcinoma
National Cancer Institute (NCI)
P1/2
CC
(43)
Autologous Bcma/Cd19 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Bcma/Gprc5D Dual-Target Car-T
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Cd19/Cd20 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Cd19/Cd22 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Cd33/Cd123 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Autologous Cd33/Cll1 Dual-Target Car-T Module
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Beijing Biotech
P1/2
CC
(43)
Showing 1676 to 1700 of 3,187 assets
Previous
Page 68 of 128
Next
